**Division of Pharmacotherapy**

Dr. David Burgess, clinical professor of pharmacotherapy, and Dr. Leroy Knodel, clinical associate professor of pharmacotherapy, have been tapped to lead the Pharmacotherapy Division. Dr. Burgess, the division head, is a nationally recognized expert in the field of infectious diseases. Dr. Knodel, assistant division head, will oversee Pharm.D. student education including expansion of the students experiential program. He will continue to serve as the Director of the Drug Information Service. The pair lead a pharmacotherapy faculty of 11 full-time faculty and 45 part-time and/or adjunct faculty.

**Burgess, Knodel named to lead division**

**Faculty**

David S. Burgess, Pharm.D., Clinical Professor, Division Head
Leroy C. Knodel, Pharm.D., Clinical Associate Professor, Hollingsworth Fellow, Assistant Division Head
Robert L. Talbert, Jr., Pharm.D., Smith Kline Professor
John G. Kuhn, Pharm.D., Glaxo Wellcome Professor
Louis C. Littlefield, Pharm.D., Sheffield Professor

Emeritus

Charles A. Walton, Ph.D., Sheffield Professor Emeritus
Henry I. Bussey, Pharm.D., Professor, Hamm Fellow
Jim M. Koeller, M.S., Professor, Lilly/Sublett Fellow
Christopher R. Frei, Pharm.D., Assistant Professor
Jodi L. Grabinski, Pharm.D., Assistant Professor
Nathan P. Wiederhold, Pharm.D., Assistant Professor
Y. W. Francis Lam, Pharm.D., Clinical Associate Professor, Burke Fellow
Stephen R. Saklad, Pharm.D., Clinical Associate Professor, Walsdorf Fellow

**Chest physicians honor Bussey**

Dr. Henry Bussey, professor of pharmacotherapy, has been honored for two web-based initiatives to manage medication therapies designed to prevent blood clots. Chest Foundation, the philanthropic arm of the American College of Chest Physicians, announced the awards totaling $185,000. He was named recipient of the GlaxoSmithKline Distinguished Scholar in Thrombosis Award and as a recipient of the Foundation’s Humanitarian Project Development Award, presented to recognize ACCP member projects and programs that improve the health of those in need.

**Talbert honored for literary feats**

The American College of Clinical Pharmacy named Dr. Robert Talbert as recipient of the Russell R. Miller Award for substantial contributions to the literature of clinical pharmacy.

In June 2008, Talbert celebrated the release of the seventh edition of Pharmacotherapy: A Pathophysiologic Approach, a publication in which he was author or co-author of six different chapters. In addition, he served as editor for the book’s cardiovascular, pulmonary and endocrine sections.
Laurajo Ryan, Pharm.D., Clinical Assistant Professor
Jennifer K. Seltzer, Pharm.D., Clinical Assistant Professor
Kimberly K. Summers, Pharm.D., Clinical Assistant Professor
Sharon A. Tschirhart, Pharm.D., Clinical Assistant Professor
Veronica S. Young, Pharm.D., Clinical Assistant Professor

Allison Cody, Pharm.D., Instructor in Clinical Pharmacy, Resident in Pharmacy Practice, Dr. Maxwell
Debra Dandridge, Pharm.D., Instructor in Clinical Pharmacy, Resident in Psychiatry, Dr. Saklad
Reed Hall, Pharm.D., Instructor in Clinical Pharmacy, Resident in Pharmacy Practice, Dr. Maxwell/Dr. Lewis
M. Lindsey Hedgepeth, Pharm.D., Clinical Instructor, Resident in Psychiatric Pharmacy Practice, Dr. Mascarenas

Kristen Hehr, Pharm.D., Instructor in Clinical Pharmacy, Resident in Pharmacy Practice, Dr. Rottman
Prudence Hofmann, Pharm.D., Instructor in Clinical Pharmacy, Resident in Pharmacy Practice, Dr. Rottman
Phillip Lai, Pharm.D., Instructor in Clinical Pharmacy, Resident in Psychiatry, Dr. Mascarenas

Asmabanu Lat, Pharm.D., Instructor in Clinical Pharmacy, Resident in Hospital Infectious Disease, Dr. Echevarria
Andrea Mora, Pharm.D. Instructor in Clinical Pharmacy, Resident in Hospital Infectious Disease, Dr. Echevarria
Kristin Reed, Pharm.D., Instructor in Clinical Pharmacy, Resident in Hospital Pharmacy Practice, Dr. Rottman
Carrie Rogers, Pharm.D., Instructor in Clinical Pharmacy, Resident in Hospital Pharmacy Practice, Dr. Rottman
Kristi Traugott, Pharm.D., Instructor in Clinical Pharmacy, Resident in Pharmacy Practice, Dr. Maxwell

Joint/Adjunct Faculty
Angela A. Allerman, Pharm.D., Clinical Assistant Professor, Pharmacoeconomic Center – Fort Sam Houston
Oralia V. Bazaldua, Pharm.D., Clinical Assistant Professor, UTHSCSA Family Practice
William H. Benefield, Jr., Pharm.D., Clinical Assistant Professor, PharMerica – San Antonio
C. Y. Jennifer Chan-Lam, Pharm.D., Clinical Assistant Professor
Elaine Chiquette, Pharm.D., Clinical Assistant Professor, AmyLin Pharmaceuticals – San Antonio
Lisa E. Farnett, Pharm.D., Clinical Assistant Professor, Sanofi Aventis – San Antonio
Catherine S. Hall, Pharm.D., Clinical Assistant Professor, San Antonio State Hospital – San Antonio
Barbara J. Hoeben, Pharm.D., Clinical Assistant Professor, Wilford Hall Medical Center, Lackland AFB – San Antonio

Nancy C. Hudepohl, Ph.D., Clinical Assistant Professor, UTHSCSA
James S. Lewis, II, Pharm.D., Clinical Assistant Professor, UTHSCSA
John H. Littlefield, Ph.D., Clinical Assistant Professor, UTHSCSA
Theresa A. Mays Hutchings, Pharm.D., Clinical Assistant Professor, Cancer Therapy & Research Center – San Antonio

Eugene Moore, Pharm.D., Clinical Assistant Professor, Pharmacoeconomic Center – Fort Sam Houston
Roger P. Potyk, Pharm.D., Clinical Assistant Professor, Pfizer, Inc. – San Antonio
Ann L. Richards, Pharm.D., Clinical Assistant Professor, San Antonio State Hospital – San Antonio
Daniel J. Still, Pharm.D., Clinical Assistant Professor, UTHSCSA
John M. Tovar, Pharm.D., Clinical Assistant Professor, UTHSCSA
Sharon M. Tramonte, Pharm.D., Clinical Assistant Professor, San Antonio State School – San Antonio
Shana K. Trice, Pharm.D., Clinical Assistant Professor, Pharmacoeconomic Center – Fort Sam Houston

Curtis L. Triplitt, Pharm.D., Clinical Assistant Professor, Texas Diabetes Institute – San Antonio
Holly N. Winkler, Pharm.D., Clinical Instructor, South Texas Veterans Health Care System – San Antonio
Edward M. Zastawny, Pharm.D., Clinical Assistant Professor, Novartis Pharmaceuticals – San Antonio

Staff
Elisa K. Fischer, Administrative Associate
Mary J. Frisce, Administrative Services Officer
Joan Jones-Stephens, B.B.A., Administrative Assistant
Jennifer Scranton Saenz, Administrative Associate
Presentations

Benefield, William
“The Role of Aripiprazole in the Treatment of Depressive Disorders.” Corpus Christi State School, Corpus Christi, TX, March ‘08.
“The Management of Treatment Resistant Depression.” Psychiatric Nursing Regional Conference, San Antonio, TX, March ‘08.
“Update in the Treatment of Anxiety Disorders.” University Learning Seminar, Athens, Greece, July ‘08.
“Metabolic Syndrome: The Dark Side to Antipsychotic Therapy” and “Psychotropic Considerations in Special Populations.” University Learning Seminar, Istanbul, Turkey, July ‘08.

Burgess, David S.
“Optimizing Outcomes in Severe Clostridium Difficile-Associated Disease: A Closer Look at Infection Control and Therapeutics Strategies.” United Regional Health Care, Wichita Falls, TX, Sept. ‘07.
“Surgical Care Improvement Project.” Texas Medical Foundation Regional Meeting, Mother Frances Hospital, Tyler, TX, Sept. ‘07, Texas Medical Foundation Regional Meeting, Providence Memorial Hospital, El Paso, TX, Nov. ‘07 and Texas Medical Foundation Regional Meeting, Mother Frances Hospital, Tyler, TX, Sept. ‘07.
“Surgical Care Improvement Project: The Antibiotic Dilemma.” VHA Texas SCIP Learning Collaborative, Dallas, TX, Oct. ‘07.
“Treating Complicated Intra-Abdominal Infections and Skin Structure Infections with Tigecycline.” Parkview Regional Hospital, Mexa, TX, March ‘08.
“Update in the Management of Gram-Negative Infections.” Annual Pharmacotherapy Education and Research Update, San Antonio, TX, April ‘08.

Bussey, Henry I.
“The Future of Oral Anticoagulation Management.” Family Practice Grand Rounds, University of Texas Health Science Center at San Antonio, San Antonio, TX, Feb. ‘08 and The President’s Medicine Grand Rounds, Texas Tech Health Science Center, El Paso, TX, March ‘08.

Dasher, James Anthony

Echevarria, Kelly L.
“Drugs and Bugs in the Rehab Patient.” Rehabilitation
Medicine Lecture Series, San Antonio, TX, April ‘08.
“Management of Clostridium-difficile Associated Diarrhea.” Infectious Diseases Core Lecture Series, San Antonio, TX, March ‘08.

Frei, Christopher R.
“Capital Campaign: Break-out Group Summaries. Excerpts from the UTCOP Faculty Retreat.” Dean’s Advisory Council Meeting, University of Texas at Austin College of Pharmacy, Austin, TX, Sept. ‘07.
“Pharm.D. and Post-Graduate Training Programs in San Antonio.” University of Texas Student Society of Health-System Pharmacists, University of Texas at Austin College of Pharmacy, Austin, TX, Nov. ‘07.
“Disparities in Utilization of Irinotecan, Oxaliplatin, and Bevacizumab, Among Young and Elderly Patients with Advanced Colorectal Cancer.” American Society of Clinical Oncology Symposia and Workshops, Gastrointestinal Cancers Symposium, Orlando, FL, Jan. ‘08.

Grabinski, Jodi L.
“Pharmacogenomics of Hormonal Therapy in Adjuvant Breast Cancer Treatment.” Pharmacuetics Seminar, University of Texas College of Pharmacy, Austin, TX, Feb. ‘08.
“Translational Research (T2), Including Practice-Based Research Networks.” College of Pharmacy Annual Retreat, University of Texas at Austin College of Pharmacy, Driftwood, TX, Aug. ‘08.

Jung Tschirhart, Sharon
“Pharmacy Residency and Fellowship Programs.” Introduction to Pharmacy Course, University of Texas at Austin College of Pharmacy, Austin, TX, March ‘08.
“Challenges in Geriatric Pharmacotherapy.” Pharmacotherapy Education and Research Center Update, San Antonio, TX, April ‘08.

Knodel, Leroy C.
“New Drug Update.” Texas Section of Women’s Health, Obstetric & Neonatal Nurses Annual Meeting, San Antonio, TX and 55th Annual Pharmacy Practice Seminar, University of Texas at Austin College of Pharmacy, Austin, TX, Sept. ‘07.
“Update on the Management of GERD.” Central East Texas Pharmacy Association, Tyler, TX, Sept. ‘07.
“Current Approaches in the Management of GERD.” San Angelo Coalition of Nurses in Advanced Practice Association, San Angelo, TX, Jan. ‘08.
“New Drug Update - 2008.” Texas Society of Health-System Pharmacists Annual Meeting, Dallas, TX, April ‘08.
“New Drug Update.” Texas Pharmacy Association Annual Rxperts Conference and Expo, Galveston, TX, July ‘08; Annual Pharmacotherapy Education and Research Center Update, San Antonio, TX, April ‘08; and Texas Pharmacy Association Annual Conference and Expo, Galveston, TX, July ‘08.

Koeller, Jim
“Economics of Cancer Care.” Huntsville Cancer Center, Huntsville, AL, Aug. ‘07.
“Disease Treatment Standardization.” Georgia Oncology Society, Augusta, GA, Sept. ‘07.
“Standardized Chemotherapy Regimens.” Cancer Center
Grand Rounds, Sioux Falls, SD, Oct. ‘07.
“Economic Analysis in Cancer.” Midwest Oncology Society Annual Meeting Keynote Address, Phoenix, AZ, Nov. ‘07.
“Cancer Disease Treatment Mapping.” Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, Jan. ‘08.
“Economics of Cancer Care.” Fred Hutchinson Cancer Center Grand Rounds, Seattle, WA, Feb. ‘08.
“Using NPs in the Community Oncology Setting.” Scripps Cancer Center Advanced Nursing Practice National Meeting, San Diego, CA, March ‘08.
“Oncology Pharmacists in Community Practice.” National Association Community Cancer Centers Economics Meeting, Baltimore, MD, April ‘08.
“Cancer Care Pharmacoconomics.” Academy of Managed Care Pharmacy National Meeting, San Francisco, CA, April ‘08.
“Disease Treatment Standardization.” Stanford Cancer Center, San Diego, CA, June ‘08.
“New Delivery Systems for Cancer Care.” Multinational Association of Supportive Care in Cancer International Meeting, Houston, TX, June ‘08.
“Cost Accounting New Cancer Treatments.” Nevada Cancer Center, Las Vegas, NV, July ‘08.

Kuhn, John G.
“Innovative Cancer Therapy for Today and Tomorrow: Focus on Targeted Therapies.” US Oncology University, Dallas, TX, March ‘08.
“Updated on Emerging Investigational Agents.” Hematology/Oncology Pharmacist Association, Anaheim, CA, June ‘08.
“Oral Anticancer Agents: Food and Drug Interactions” and “Cardiovascular Effects of the ErbB2 and VEGFR Inhibitors.” European Conference Oncology Pharmacy, Hamburg, Germany, Jan. ‘08.
“Oral Anticancer Agents.” Pharmacotherapy Education and Research Center Update, San Antonio, TX, April ‘08.

Lewis, James S.
“ICAAC 2007 Update” and “Therapeutic Drug Monitoring of Azoles in Invasive Aspergillosis.” Bone Marrow Transplant Pharmacists, American Society for Blood and Marrow Transplantation Tandem Meetings, San Diego, CA, Feb. ‘08.
“Application of Pharmacology to In-the-Trenches Antifungal Therapy.” Focus on Fungal Infections 18, San Antonio, TX, March ‘08.
“Serious Fungal Infections: New Opportunities in the Prevention and Management of Invasive Aspergillosis.” National Teleconference, April ‘08.

Mascareñas, Cynthia A.
“Psychopharmacology of Antidepressants,” “Psychopharmacology of Antipsychotics” and “Cytochrome P450 System.” Psychopharmacology Seminars, University of Texas Health Science Center at San Antonio Psychiatry Residency Program, San Antonio, TX, Jan. and Feb. ‘08.
“Depression and Anxiety in Primary Care.” National Veteran Affairs Physician Assistant Association, San Antonio, TX, Aug. ‘08.

Maxwell, Pamela R.
“Immunosuppression in Solid Organ Transplantation.” Transplant Surgery Team Residents and Medical Students, University Hospital, San Antonio, TX, Sept. ‘07.
“Summary of 2007 Transplant Pharmacy Expenditures.” Solid Organ Transplant Grand Rounds, University of Texas Health Science Center at San Antonio, San Antonio, TX, Jan. ‘08.
“Transplant for Dummies.” Pharmacotherapy Education and Research Center Update, San Antonio, TX, April ‘08.
“Health System Pharmacy Practice.” Summer Med Ed Program, University of Texas Health Science Center at San Antonio, San Antonio, TX, June ‘08.

Richards, Ann
“Regulatory Issues in Pharmacy Practice.” BCPP Exami-
nation Review and Recertification Course, April ‘08.

**Rottman, Rebecca**

**Ryan, Laurajo**
“Diabetes Update.” Pharmacotherapy Education Research Center Update, San Antonio, TX, April ‘08.
“Polycystic Ovarian Syndrome” and “Cardiovascular Disease and Women.” Texas Society of Health-Systems Pharmacists, Dallas, TX, April ‘08.
“Diabetes and Insulin Use.” University Hospital, San Antonio, TX, May ‘08.

**Saklad, Stephen R.**
“Update on Schizophrenia Treatments.” University of Texas Health Science Center at San Antonio Psychiatry Residents, San Antonio, TX, Nov. ‘07.
“Genomic Implications for the Field of Mental Health.” Mental Health America of Texas, Austin, TX, Dec. ‘07.
“Innovations in Enhancing Schizophrenia Treatment.” San Antonio State Hospital, San Antonio, TX, March ‘08.
“Schizophrenia.” San Antonio State Hospital and San Antonio State School, San Antonio, TX, April ‘08.
“Treatment of Psychiatric Emergencies.” Austin Psychiatrists, Austin, TX, May ‘08.
“Innovations in the Treatment of Major Depressive Disorder.” Austin Psychiatrists, Austin, TX, May ‘08.
“Polypharmacy: Evidence-Based Review.” Lehey/Dartmouth Annual Pharmacy Cooperative Educational Program Lake Morey Resort, VT, June ‘08.
“Treatment of Refractory Depression in the Developmentally Delayed Individual.” Corpus Christi State School, Corpus Christi, TX, June ‘08.
“Can Formulation Technology Speed Drug Development and Improve Therapeutic Profiles for Antipsychotics?” Meeting of Schizophrenia International Research Society, Venice, Italy, June ‘08.
“Evidenced Based Round Table.” Zyprexa Payer Marketing Division at Eli Lilly, Detroit, MI, July ‘08.
“Treatment Refractory Depression.” San Antonio Psychiatrists, San Antonio, TX, July ‘08.

“Adjunctive Use of Antipsychotics in Depression.” Dallas Physicians, Dallas, TX, July ‘08.

**Summers, Kimberly K.**

**Talbert, Robert L.**
“Hypertensive Crisis.” Department of Family and Community Medicine, University of Texas Health Science Center at San Antonio, Feb. ‘08.
“Update on the Management of Hypertension.” Corpus Christi Physicians, Corpus Christi, TX, March ‘08.
“Update on Thyroid Disease.” PriMed Seminar Houston and Dallas TX, March ‘08; Philadelphia, PA, Atlanta, GA, Orlando, FL, May ‘08; Cary, NC, May ‘08 and Miami, FL, June ‘08.
“Levothyroxine Bioequivalence.” Texas Society of Health-System Pharmacists, Dallas, TX, April ‘08.
“Antiplatelet Therapy for Acute Coronary Syndromes.” Pharmacotherapy Education and Research Center Update, San Antonio, TX, April ‘08.
“Management of Low HDL.” Academy of Managed Care
Wiederhold, Nathan P.


“Therapeutic Drug Monitoring of Antifungals: Is it Time?” Focus on Fungal Infections 18, San Antonio, TX, March ‘08.

“New Antifungals to Therapeutic Drug Monitoring with the Echinocandin Conundrum In Between: An Update on Invasive Fungal Infections.” Pharmacotherapy Education and Research Center Update, San Antonio, TX, April ‘08.


“Therapeutic Drug Monitoring for Antifungals: What is the Evidence?” Texas Infectious Disease Society Annual Meeting, San Antonio, TX, June ‘08.

Young, Veronica S. L.

“Online Resources for Pharmacy Preceptors and Students.” Pharmacy Preceptor Conference, San Antonio, TX, May ‘08.

Publications

Burgess, David S.


(Cadena, Taboada, Ma, Lewis, Freytes, Patterson) “Antibiotic Cycling to Decrease Antibiotic Resistance: A 5-year Experience on a Bone Marrow Transplant Unit.” Bone Marrow Transplantation (40), pp. 151-155, ’07.


(Cota, Grabinski, Talbert, Rogers, Edlind, Wiederhold) “Increases in SLT2 Expression and Chitin Content are Associated with Incomplete Killing of Candida glabrata by Caspofungin.” Antimicrobial Agents and Chemotherapy 52, pp. 1144-1146, ’08.

(Rapp) “Bugs Versus Drugs: Addressing the Pharmacist’s


(Padilla, Carden, Attridge) “In-Vitro Activity Of Colistin, Amikacin and In Combination Against Multidrug-Resistant Acinetobacter baumannii In A Pharmacodynamic-Pharmacokinetic Model” and (Attridge, Carden, Padilla) “Colistin and Rifampicin Alone And In Combination Against Multidrug-Resistant Acinetobacter baumannii Using An In Vitro Pharmacokinetic-Pharmacodynamic Model.” 4th Annual Louis C. Littlefield Celebrating Pharmacy Research Excellence Day, Austin, TX, April ’08. (Abstracts)

Bussey, Henry I.


Chan, Jennifer


Echevarria, Kelly L.


Frei, Christopher R.

(Burgess, Carden, Wickes, Lewis, Jorgensen) “In Vitro Activity of Piperacillin/Tazobactam (PTZ), Cefepime (CFP), and Meropenem Against ESBL Producing CTX-M-15 and SHV-12.” 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Annual International Meeting, Chicago, IL, Sept. ’07. (Abstract)


(Oramasionwu, Mohr, Klepser, Barner) “Vaccine Adherence and Perceptions Among Infectious Diseases Pharmacists.” American Journal of Health-System Pharmacy 65, pp. 1500-1501, ’08.

(McKibbin, Greene, Kwan, Simon, Koeller) “Disparities in the Utilization of Chemotherapy and Monoclonal Antibody Therapy for Advanced Colorectal Cancer Among Elderly Patients in the Community Oncology Setting.” The Oncologist 13, pp. 876-885, ’08. (Abstract)


(Chi, Tschirhart, Erwin) “Appropriateness of Anticoagulation Based on CHADS2 Stroke Risk Stratification in Elderly Patients with Atrial Fibrillation.” Alcalde XXII: Southwest Leadership Conference, Dallas, TX, April ‘08. (Abstract)

(Hughes, Green, Maxwell, Lewis) “Continuous vs. Intermittent Infusion Oxacillin for the Treatment of Methicillin-Sensitive Staphylococcus aureus Infective Endocarditis.” 4th Annual Louis C. Littlefield Celebrating Pharmacy Research Excellence Day, Austin, TX, April ‘08. (Abstract)


(Jaso, Oramasionwu, Mortensen, Restrepo, Ruiz, Jimenez, Sikirica, Raut, Schein) “Comparison of Levofoxacin 750mg daily vs. Ceftriaxone 1g plus Azithromycin 500mg Daily for the Empiric Treatment of Hospitalized Community-Acquired Pneumonia Patients.” American Society of Health-System Pharmacists Summer Meeting and Exhibition, Seattle, WA, June ‘08. (Abstract)

Grabinski, Jodi L.


Johnson, Melissa A.

Pharmacy & Therapeutics Committee Newsletter: A Quarterly Publication Reporting the News of CHRIS-TUS Santa Rosa P&T Committees.

Jung-Tschirhart, Sharon

(Brandt, Jeffery, Rickman, Nelson, Nimmo) “Educational Outcomes, Goals, and Objectives for Postgraduate Year Two Pharmacy Residencies in Geriatrics.” ASHP Commission on Credentialing, March 8, 2008.
Koeller, Jim
(McKibbin, Kwan, Simon) “Rapid Adoption of Chemotherapy Regimens for Advanced Colorectal Cancer in the Community Oncology Setting.” American Society Clinical Oncology 26, pp. 352, ‘08. (Abstract)


Kuhn, John G.


Lam, Y.W. Francis
Mascarenas, Cynthia

Maxwell, Pamela R.
(Brady, Green) “Retrospective Evaluation of Outcomes in Renal Transplant Recipients Receiving rATG Induction Therapy Versus No Induction Therapy,” (Hughes, Frei, Green, Lewis) “Continuous vs. Intermittent Infusion Oxacillin for the Treatment of Methicillin-Sensitive Staphylococcus aureus Infective Endocarditis,” (Franco, Green, Barthol) “Anticoagulation Patient Safety Goal Compliance at a University Health System: How Are We Achieving the Goal?” (Hall, Speeg, Green, Lewis) “Predictors of Outcomes in Hepatitis C-related Liver Transplants: How are We Doing?” *Alcalde XXII: Southwest Leadership Conference*, Dallas, TX, April ‘08. (Abstracts)
(Hughes, Frei, Green, Lewis) “Continuous vs. Intermittent Infusion Oxacillin for the Treatment of Methicillin-Sensitive Staphylococcus aureus Infective Endocarditis,” (Franco, Green, Barthol) “Anticoagulation Patient Safety Goal Compliance at a University Health System: How Are We Achieving the Goal?” (Hall, Speeg, Green, Lewis) “Predictors of Outcomes in Hepatitis C-related Liver Transplants: How are We Doing?” and (Brady, Green) “Retrospective Evaluation of Outcomes in Renal Transplant Recipients Receiving rATG Induction Therapy Versus No Induction Therapy.” *4th Annual Louis C. Littlefield Celebrating Pharmacy Research Excellence Day*, Austin, TX, April ‘08. (Abstracts)

Moore, Tera Dawn Critchfield

Rottman, Rebecca

Ryan, Laura Jo

Seltzer, Jennifer K.
“Five-Year Investigation of Pharmacoepidemiology Among Patients with Community-Acquired, Healthcare-Associated, Hospital-Acquired, and Ventilator-Associated Pneumonia.” *American College of Clinical

**Talbert, Robert L.**


(Cota, Grabinski, Burgess, Rogers, Edlind, Wiederhold) “Increases in SLT2 Expression and Chitin Content are Associated with Incomplete Killing of Candida glabrata by Caspofungin.” *Antimicrobial Agents and Chemotherapy* 52, pp. 1144-1146, ‘08.


**Wiederhold, Nathan P.**


(Cota, Grabinski, Rogers, Edlind) “Association Between the Cell Wall Integrity Pathway and Chitin Content in the Attenuation of Caspofungin Activity in Candida glabrata.”

(Vallor, Najvar, Kirkpatrick, Bocanegra, Molina, Olivo, Graybill, Patterson) “Assessment of Serum Beta-1,3-Glucan as a Measure of Disease Burden in Invasive Pulmonary Aspergillosis.”


(Cota, Grabinski, Burgess, Rogers, Edlind) “Increases in SLT2 Expression and Chitin Content are Associated with Incomplete Killing of Candida glabrata by Caspo-
fungin” and (Najvar, Vallor, Kirkpatrick, Bocanegra, Molina, Olivo, Graybill, Patterson) “Assessment of Serum (1→3)-β-D-Glucan as a Measure of Disease Burden in a Murine Model of Invasive Pulmonary Aspergillosis.” Antimicrobial Agents and Chemotherapy 52, pp. 1144-1146 and 1176, ’08. (Abstract)


Veronica S. L.

“Food Medication Interactions.” Food-Medication Interactions, 15th ed., Young, Crowe, Elbe, Epstein, (eds), Birchrunville, PA, pp.1-380, ’08. (Co-Editor)
### Grants and Contracts

#### Funds Directed through UT Austin Accounts

<table>
<thead>
<tr>
<th>FUNDING SOURCE</th>
<th>AMOUNT</th>
<th>TITLE</th>
<th>INVESTIGATOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>University Health System</td>
<td>$26,000</td>
<td>Inter Agency Contract with University Health System</td>
<td>Burgess</td>
</tr>
<tr>
<td>Christus Santa Rosa</td>
<td>55,073</td>
<td>Pediatric Clinical Pharmacy Agreement</td>
<td>Burgess</td>
</tr>
<tr>
<td>Children’s Hospital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Various Donors</td>
<td>14,750</td>
<td>Pharmacotherapy Education and Research Center Update</td>
<td>Burgess</td>
</tr>
<tr>
<td>Wyeth Pharmaceuticals</td>
<td>16,000</td>
<td>Piperacillin-tazobactam in Combination with Amikacin, Tobramycin, or</td>
<td>Burgess</td>
</tr>
<tr>
<td></td>
<td></td>
<td>gentamicin against ESBL K pneumoniae in an in vitro model</td>
<td></td>
</tr>
<tr>
<td>OrthoMcNeil Janssen Pharmaceuticals</td>
<td>35,280</td>
<td>Impact of a Network-wide Clinical Pathway on Health-outcomes for</td>
<td>Frei</td>
</tr>
<tr>
<td></td>
<td>(7,488)</td>
<td>Hospitalized Patients with Community-acquired Pneumonia</td>
<td></td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>17,208</td>
<td>Graduate School Diversity Mentoring Fellowship</td>
<td>Frei</td>
</tr>
<tr>
<td></td>
<td>(5,736)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graduate School, UT Austin</td>
<td>23,635</td>
<td>Graduate School Diversity Mentoring Fellowship</td>
<td>Frei</td>
</tr>
<tr>
<td>Texas Health and Human Services Commission</td>
<td>73,718</td>
<td>Drug Information Services for medicaid DUR</td>
<td>Knodel</td>
</tr>
<tr>
<td>CyDex Pharmaceuticals</td>
<td>114,500</td>
<td>Characterization of Aerosolized Voriconazole for Invasive Aspergillosis</td>
<td>Wiederhold</td>
</tr>
<tr>
<td></td>
<td>(15,500)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Society of Infectious Diseases Pharmacists</td>
<td>8,500</td>
<td>Cell Wall Integrity Pathway and Clinical Attenuation of Echinocandin Activity</td>
<td>Wiederhold</td>
</tr>
</tbody>
</table>

Subtotal Division of Pharmacology and Toxicology

**Direct** $384,664

**Indirect** ($21,236)

### Funds Directed through Other UT System Accounts

<table>
<thead>
<tr>
<th>FUNDING SOURCE</th>
<th>AMOUNT</th>
<th>GRANT TITLE</th>
<th>INVESTIGATOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Clinical Pharmacy Res. Inst.</td>
<td>$10,000</td>
<td>Anticoagulation Training Program</td>
<td>Bussey</td>
</tr>
<tr>
<td>OrthoMcNeil Janssen Pharmaceuticals</td>
<td>42,500</td>
<td>Hospitalized Patients with Pneumonia, Bacteremia, or Both: A Multi-center Study of Patient Characteristics, Treatment Patterns, and Outcomes</td>
<td>Frei</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>200,649</td>
<td>Phase I/II PK/PD Studies of Agents for CNS Malignancies</td>
<td>Kuhn</td>
</tr>
<tr>
<td>National Cancer Institute</td>
<td>(57,922)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UT Health Science Center</td>
<td>12,207</td>
<td>Secondary Prevention in Small Subcortical Strokes (SPS3)</td>
<td>Talbert</td>
</tr>
<tr>
<td></td>
<td>(2,402)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>25,000</td>
<td>Rate of In Vitro and In Vivo Activity of Anidulafungin Agastin C. albicans and C. parapsilosis</td>
<td>Wiederhold</td>
</tr>
<tr>
<td></td>
<td>(7,500)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schering-Plough</td>
<td>57,620</td>
<td>In Vivo Efficacy of Posaconazole Against Fusarium Species with Reduced In Vitro Susceptibility</td>
<td>Wiederhold</td>
</tr>
<tr>
<td></td>
<td>(17,286)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Subtotal Division of Pharmacotherapy
Direct $347,976
(Indirect) $(85,110)

Funds Directed through Other Agencies or Institutions

<table>
<thead>
<tr>
<th>FUNDING SOURCE</th>
<th>AMOUNT</th>
<th>GRANT TITLE</th>
<th>INVESTIGATOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Diagnostics</td>
<td>$42,000</td>
<td>Triple Intervention in Anticoagulation Management</td>
<td>Bussey</td>
</tr>
<tr>
<td>Am Coll Clin Pharm Res Inst</td>
<td>1,200</td>
<td>Anticoagulation Training Program (ACNA support)</td>
<td>Bussey</td>
</tr>
<tr>
<td>Am Coll Clin Pharm Res Inst</td>
<td>4,000</td>
<td>Anticoagulation Training Program (trainee stipend)</td>
<td>Bussey</td>
</tr>
<tr>
<td>National Institutes of Health Loan Repayment Program (NIAID)</td>
<td>5,484</td>
<td>Antibiotic Pharmacodynamics</td>
<td>Frei</td>
</tr>
<tr>
<td>National Institutes of Health Loan Repayment Program (NIAID)</td>
<td>9,089</td>
<td>Oncology Pharmacogenomics</td>
<td>Grabinski</td>
</tr>
<tr>
<td>Texas Health/Human Services Commission</td>
<td>73,718</td>
<td>Drug Information Services for Medicaid DUR</td>
<td>Knodel</td>
</tr>
<tr>
<td>National Institutes of Health (NIAID)</td>
<td>12,000</td>
<td>A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 (Proleukin) in Patients With HIV-1 Infection and CD4+ Cell Counts &gt; 300/mm3: Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT)</td>
<td>Summers</td>
</tr>
<tr>
<td>National Institutes of Health (NIAID)</td>
<td>11,000</td>
<td>A Randomized Study of the Efficacy of Subcutaneous Interleukin-2 (IL-2) in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT)</td>
<td>Summers</td>
</tr>
<tr>
<td>National Institutes of Health (CPCRA)</td>
<td>5,000</td>
<td>A Large, Simple Trial Comparing Two Strategies for Management of Anti-retroviral Therapy (SMART)</td>
<td>Summers</td>
</tr>
<tr>
<td>National Institutes of Health (CPCRA)</td>
<td>3,000</td>
<td>A Study of Aldesleukin With and Without Antiretroviral Therapy (STALWART)</td>
<td>Summers</td>
</tr>
<tr>
<td>NAPO Pharmaceuticals</td>
<td>15,000</td>
<td>Anti-diarrhea Therapy in HIV Disease-Emerging Treatment Concepts (ADVENT)</td>
<td>Summers</td>
</tr>
</tbody>
</table>

Subtotal Division of Pharmacotherapy
Direct $181,491
(Indirect) $(0)

Other Research Collaborations in which Faculty Participated Without Account Signature Authority

<table>
<thead>
<tr>
<th>PHARMACEUTICALS</th>
<th>PROJECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pharmaceuticals</td>
<td>A Phase I, Open Label, Single Arm, Fixed-Sequence Study to Evaluate the Effect of Multiple Dose Administration of PF-00299804 on the Single Dose Pharmacokinetics of Dextromethorphan in Cancer Patients with Advanced Refractory Solid Tumors</td>
</tr>
<tr>
<td>Roche Diagnostics Inc.</td>
<td>A Pilot Study to Assess the Impact of Triple Intervention (Self-Testing, Daily Vitamin K Supplementation, and Online Management) on Anticoagulation Control and Efficiency</td>
</tr>
<tr>
<td>Company</td>
<td>Project Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Bristol-Meyers</td>
<td>Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects with Hepatic Impairment (A1266917)</td>
</tr>
<tr>
<td>Tibotec</td>
<td>Early Access of TMC125 in Combination with Other Antiretrovirals (ARVs) in Treatment Experienced HIV-1 Infected Subjects with Limited Treatment Options (TMC125-C214)</td>
</tr>
<tr>
<td>Merck</td>
<td>Early Access of MK-0518 in Combination with an Optimized Background Antiretrovirals (OBT) in Highly Treatment Experienced HIV-1 Infected Patients with No Treatment Options (MK-0518 023-00)</td>
</tr>
<tr>
<td>BMS</td>
<td>A Phase IV, Multicenter, Cross-sectional Study to Evaluate I50L Substitution Among Subjects Experiencing Virological Failure on a HAART Regimen Containing Atazanavir (ATZ) (IMPACT Trial) Containing Atazanavir (ATZ)</td>
</tr>
</tbody>
</table>

**Total Division of Pharmacology and Toxicology**

<table>
<thead>
<tr>
<th>Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct</td>
<td>$914,131</td>
</tr>
<tr>
<td>(Indirect)</td>
<td>($106,346)</td>
</tr>
</tbody>
</table>